

# **Andrology**

## **Male Fertility and Sterility**

**Edited by**

*John D. Paulson*

*Andrés Negro-Vilar*

*Elkin Lucena*

*Luciano Martini*

# ANDROLOGY

## Male Fertility and Sterility

Edited by

**JOHN D. PAULSON**

*Alexandria Infertility Associates  
Alexandria, Virginia*

**ANDRÉS NEGRO-VILAR**

*Section of Reproductive Neuroendocrinology  
Laboratory of Reproduction and Developmental Toxicology  
NIEHS  
National Institutes of Health  
Research Triangle Park, North Carolina*

**ELKIN LUCENA**

*Cecolfes  
Bogota, Colombia*

**LUCIANO MARTINI**

*Department of Endocrinology  
University of Milan  
Milan, Italy*

1986



ACADEMIC PRESS, INC.

**Harcourt Brace Jovanovich, Publishers**

Orlando San Diego New York Austin  
Boston London Sydney Tokyo Toronto

COPYRIGHT © 1986 BY ACADEMIC PRESS, INC.  
ALL RIGHTS RESERVED.  
NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR  
TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC  
OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR  
ANY INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT  
PERMISSION IN WRITING FROM THE PUBLISHER.

ACADEMIC PRESS, INC.  
Orlando, Florida 32887

*United Kingdom Edition published by*  
ACADEMIC PRESS INC. (LONDON) LTD.  
24-28 Oval Road, London NW1 7DX

**Library of Congress Cataloging in Publication Data**

Main entry under title:

Andrology : male fertility and sterility.

Includes index.

1. Generative organs, Male—Diseases. 2. Infertility,  
Male. 3. Andrology. I. Paulson, John D. [DNLM:  
1. Fertility. 2. Genitalia, Male—physiology.  
3. Infertility, Male. 4. LH-FSH Releasing Hormone—  
pharmacodynamics. WJ 702 A5743]  
RC875.A53 1986 616.6'9 85-28749  
ISBN 0-12-547560-8 (alk. paper)

PRINTED IN THE UNITED STATES OF AMERICA

86 87 88 89

9 8 7 6 5 4 3 2 1

To James C. Warren, M.D., Ph.D., teacher, scholar, and friend, who has contributed so much to reproductive medicine.

## CONTRIBUTORS

Numbers in parentheses indicate the pages on which the authors' contributions begin.

- Judith N. Albarelli** (511), Alexandria Infertility Associates, Alexandria, Virginia 22304
- S. Andò** (201), Department of Cellular Biology, University of Calabria, 87030 Arcavachea di Rende (Cs), Italy
- Pierre Asmar** (511), Alexandria Infertility Associates, Alexandria, Virginia 22304
- A. Banchini** (189), Istituto di Clinica Medica Generale e Terapia Medica, University of Parma, 43100 Parma, Italy
- José L. S. Barañao** (85), Instituto de Biología y Medicina Experimental, Buenos Aires 1428, Argentina
- A. Bartke** (101), Department of Physiology, Southern Illinois University School of Medicine, Carbondale, Illinois 62901
- B. Norman Barwin** (461), The Fertility Center, Department of Obstetrics and Gynecology, University of Ottawa, Ottawa General Hospital, Ottawa, Ontario K2A 3Z3, Canada
- Damasía Becú de Villalobos** (59), Instituto de Biología y Medicina Experimental, Buenos Aires 1428, Argentina
- Alain Bélanger** (39), Departments of Molecular Endocrinology and Medicine, Laval University Medical Center, Quebec G1V 4G2, Canada
- Eduardo Bustos-Obregón** (293), Department of Cell Biology and Genetics, Laboratory of Reproductive Biology, University of Chile, Faculty of Medicine, 13898 Santiago, Chile
- Juan C. Calvo** (85), Instituto de Biología y Medicina Experimental, Buenos Aires 1428, Argentina
- D. Canale** (341), Andrology Center—First Medical Clinic, University of Pisa, 56100 Pisa, Italy
- Lucia Castellani-Ceresa** (313), Departments of Biology, Zoology and Cytology, University of Milan, Milan 20133, Italy
- Eduardo H. Charreau** (85), Instituto de Biología y Medicina Experimental, Buenos Aires 1428, Argentina

- John T. Clark** (125), Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, Florida 32610
- Roberto Colombo** (313), Departments of Biology, Zoology and Cytology, University of Milan, Milan 20133, Italy
- Frank H. Comhaire** (253), Department of Endocrinology and Metabolic Diseases, State University Hospital, B-9000 Ghent, Belgium
- Domenico Conte** (175), Cattedra de Andrologia, Istituto di Clinica Medica V, Università di Roma, 00100 Rome, Italy
- Susan L. Dalterio** (161), Department of Pharmacology, The University of Texas Health Sciences Center at San Antonio, San Antonio, Texas 78284
- André Dupont** (39), Departments of Molecular Endocrinology and Medicine, Laval University Medical Center, Quebec G1V 4G2, Canada
- R. Eliasson** (331), Reproductive Physiology Unit, Department of Physiology, Karolinska Institutet, Faculty of Medicine, S-104 01 Stockholm, Sweden
- Robert F. Harrison** (427), Department of Obstetrics and Gynaecology, Trinity College Dublin, Rotunda Hospital, Dublin 1, Ireland
- R. N. Heasley** (491), Department of Midwifery and Gynaecology, The Queen's University of Belfast, Belfast BT 12 6BJ, Northern Ireland
- Zwi T. Homonnai** (377), Soferman Institute for the Study of Fertility, Hakirya Serlin Maternity Hospital, Tel Aviv-Jaffo, Israel
- Aldo Isidori** (175), Cattedra de Andrologia, Istituto di Clinica Medica V, Università di Roma, 00100 Rome, Italy
- Ø. Johnsen** (331), Reproductive Physiology Unit, Department of Physiology, Karolinska Institutet, Faculty of Medicine, S-104 01 Stockholm, Sweden
- Pushpa S. Kalra** (125), Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, Florida 32610
- Evelyn Karson** (475), Alexandria Infertility Associates, Alexandria, Virginia 22304
- Alpay Kelâmi** (619), Department of Urology, Klinikum Steglitz, Free University of Berlin, D-1000 Berlin 45, Federal Republic of Germany
- Avraham Kogosowski** (377), Soferman Institute for the Study of Fertility, Hakirya Serlin Maternity Hospital, Tel Aviv-Jaffo, Israel
- Fernand Labrie** (39), Departments of Molecular Endocrinology and Medicine, Laval University Medical Center, Quebec G1V 4G2, Canada
- Salvatore Leto** (415, 451), Washington Fertility Study Center, Washington, D.C. 20037
- Carlos Libertun** (59), Instituto de Biología y Medicina Experimental, Buenos Aires 1428, Argentina

- Elkin Lucena** (549, 553), Cecolfes, Bogota, Colombia
- Luciano Martini** (149), Department of Endocrinology, University of Milan, 20129 Milan, Italy
- G. F. Menchini-Fabris** (341), Andrology Center—First Medical Clinic, University of Pisa, 56100 Pisa, Italy
- Andrés Negro-Vilar** (3), Section of Reproductive Neuroendocrinology, Laboratory of Reproductive and Developmental Toxicology, NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709
- Hector Obando** (549, 553), Cecolfes, Bogota, Colombia
- L. Olivieri** (341), Andrology Center—First Medical Clinic, University of Pisa, 56100 Pisa, Italy
- John D. Paulson** (415, 451, 475, 511), Alexandria Infertility Associates, Alexandria, Virginia 22304
- Gedalia F. Paz** (377), Soferman Institute for the Study of Fertility, Haki-rya Serlin Maternity Hospital, Tel Aviv-Jaffo, Israel
- Kenneth L. Polakoski** (359), Department of Obstetrics and Gynecology, Washington University School of Medicine, Saint Louis, Missouri 63110
- H.-H. Riedel** (575), Department of Obstetrics and Gynecology, University of Kiel and Michaelis-Midwifery School, 2300 Keil, Federal Republic of Germany
- Nelson Rodrigues-Netto, Jr.** (233), Division of Urology, University of Campinas Medical School-UNICAMP, 01413 São Paulo, Brazil
- Juergen Sandow** (15), Hoechst AG, Pharmacology H 821, D-6230 Frankfurt 80, Federal Republic of Germany
- Wolf-Bernhard Schill** (599), Andrology Unit, Department of Dermatology, University of Munich, D-8000 Munich 2, Federal Republic of Germany
- Stanwood S. Schmidt** (561), Department of Urology, University of California, San Francisco, California 94143
- J. K. Sherman** (517), Department of Anatomy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205
- Sidney Shulman** (399), Sperm Antibody Laboratory, Metropolitan Hospital, New York Medical College, New York, New York 10029, and Fertility Diagnostics, Inc., New York, New York 10025
- Mark S. Siegel** (359), Department of Obstetrics and Gynecology, Washington University School of Medicine, Saint Louis, Missouri 63110
- George Speck** (511), Alexandria Infertility Associates, Alexandria, Virginia 22304
- Marta Tesone** (85), Instituto de Biología y Medicina Experimental, Buenos Aires 1428, Argentina

- W. Thompson** (491), Department of Midwifery and Gynaecology, The Queen's University of Belfast, Belfast BT 12 6BJ, Northern Ireland
- Roland R. Tremblay** (273), Department of Medicine, Laval University, Quebec G1V 4G2, Canada
- G. Valenti** (189), Istituto di Clinica Medica Generale e Terapia Medica, University of Parma, 43100 Parma, Italy
- S. Voliani** (341), Andrology Center—First Medical Clinic, University of Pisa, 56100 Pisa, Italy
- Leah Yogev** (377), Soferman Institute for the Study of Fertility, Hakirya Serlin Maternity Hospital, Tel Aviv-Jaffo, Israel
- S. Zoppi** (149), Department of Endocrinology, University of Milan, 20129 Milan, Italy



## PREFACE

Andrology has recently become an autonomous discipline. It can be defined as a multidisciplinary field dealing with the pathology and physiology of male reproductive functions. Research in this area contributes to the regulation of male reproduction both in fertility regulation and in the correction of infertility. Because of its interdisciplinary nature, information from individuals in one area may be biased toward approaches regarding the male reproductive system. Various specialists must understand the indications and limits of other specialists with whom they may be collaborating.

Volumes such as this one will bridge the gap of knowledge among those treating the male for andrological problems. The contributions, by leaders in their respective fields, provide background material as well as state of the art findings.

The topics included range from neuroendocrinology of the male to clinical evaluation and treatment. Novel aspects include the use of LHRH analogs for both infertility and fertility regulation and the treatment of prostate cancer. Artificial insemination has been discussed in great detail, covering indications and practical procedures. Sections on selected topics, including surgery, varicocele, the regulation of sperm motility, and immunoandrology, provide insights into the physiology and therapy of andrological problems.

John D. Paulson  
Andrés Negro-Vilar  
Elkin Lucena  
Luciano Martini

# CONTENTS

CONTRIBUTORS  
PREFACE

xix  
xxiii

## I / LHRH and Its Role in Male Fertility

### 1 / LHRH: PHYSIOLOGY, PHARMACOLOGY, AND ITS ROLE IN FERTILITY REGULATION

*Andrés Negro-Vilar*

I. Introduction	3
II. Functional Anatomy of the LHRH System	4
III. Physiological Regulation of LHRH	5
IV. Pharmacological Regulation of LHRH Function	7
V. Role of Endogenous Opiate Peptides on LHRH Regulation	8
VI. Regulation of Pulsatile Gonadotropin Release	9
VII. Conclusion	10
References	11

### 2 / THERAPEUTIC USE OF LHRH ANALOGS IN REPRODUCTIVE DISORDERS

*Juergen Sandow*

I. Introduction	15
II. Pituitary Desensitization	16
III. Cryptorchidism	19
IV. Hypogonadism	19
V. Precocious Puberty	20
VI. Contraception	22
VII. Endometriosis	26
VIII. Hormone-Dependent Tumors	27
IX. Conclusions	30
References	31

### 3 / COMBINED THERAPY WITH AN LHRH AGONIST AND A PURE ANTIANDROGEN IN PROSTATE CANCER

*Fernand Labrie, André Dupont, and Alain Bélanger*

I. Introduction	39
II. Previous Treatments: Orchiectomy and Estrogens	39

III. Medical Castration with LHRH Agonists	40
IV. Combined Treatment with an LHRH Agonist and a Pure Antiandrogen	42
V. Conclusions	50
References	52

## II / Neuroendocrine Aspects of Male Reproduction

### 4 / SEROTONIN AND MALE NEUROENDOCRINE FUNCTION

*Damasia Becú de Villalobos and Carlos Libertun*

I. Introduction	59
II. Serotonin and Hormone Secretion	61
III. Serotonin and Drugs: Serotonin as a Mediator of Cimetidine-Induced Prolactin Release in Male Rats	71
IV. Discussion	76
References	79

### 5 / DIABETES AND MALE REPRODUCTIVE FUNCTIONS

*Marta Tesone, Juan C. Calvo, José L. S. Barañao, and Eduardo H. Charreau*

I. Introduction	85
II. Streptozotocin-Induced Diabetic Rat and Replacement Insulin Treatment: A Model for the Study of Male Diabetes Disturbances	85
III. Effects of Diabetes on Testicular and Sex Gland Weights	86
IV. Diabetes and Serum LH Bioactivity	86
V. Diabetes and Leydig Cell LH Receptors	88
VI. Testicular Response to Exogenous Gonadotropin	89
VII. Diabetes and Androgen Binding Protein Production	93
VIII. Diabetes Effect on Androgen Binding Sites and 5 $\alpha$ -Reductase Activity in Prostatic Gland	94
IX. Concluding Remarks	96
References	97

### 6 / HYPERPROLACTINEMIA AND MALE REPRODUCTION

*A. Bartke*

I. Effects of Hyperprolactinemia in Men	101
II. Experimentally Induced Hyperprolactinemia	103
III. Mechanisms Responsible for the Effects of Hyperprolactinemia on Male Reproductive Functions	109
References	117

**7 / DOPAMINE, HYPERPROLACTINEMIA, AND SEXUAL BEHAVIOR***Pushpa S. Kalra and John T. Clark*

I. Introduction	125
II. Sexual Activity in Male Rats	127
III. Preoptic Area and Male Sexual Activity	128
IV. Central Dopamine Systems	130
V. Pharmacological Studies	133
VI. Physiological Studies	137
VII. Conclusions	142
References	143

**8 / MODE OF ACTION OF ANDROGENS IN NEUROENDOCRINE STRUCTURES***Luciano Martini and S. Zoppi*

I. Introduction	149
II. Physiological Role of the 5 $\alpha$ -Reduced Metabolites of Testosterone	151
III. Mechanisms of Action of the 5 $\alpha$ -Reduced Metabolites of Testosterone	155
References	157

**9 / MARIHUANA AND REPRODUCTIVE FUNCTIONS***Susan L. Dalterio*

I. Introduction	161
II. Methods and Procedures	162
III. Results	163
IV. Discussion	169
V. Summary	171
References	171

**III / Clinical Endocrinology and Varicocele in Male Reproduction****10 / PHYSIOLOGICAL AND CLINICAL IMPLICATIONS OF TESTICULAR PROSTAGLANDIN ACTIVITY***Aldo Isidori and Domenico Conte*

I. Testis	175
II. Epididymis	178
III. Accessory Glands and Seminal Prostaglandins	179
IV. Effects of Prostaglandin Administration	181
References	185

## 11 / PITUITARY FUNCTION AFTER BILATERAL ORCHIECTOMY OR CYPROTERONE ACETATE TREATMENT

*G. Valenti and A. Banchini*

I. Introduction	189
II. Endocrine Side Effects of Bilateral Orchiectomy	189
III. Endocrine Side Effects of Treatment with Cyproterone Acetate (Alone or Combined with Bilateral Orchiectomy)	194
IV. Conclusion	197
References	198

## 12 / LEYDIG CELL FUNCTION IN VARICOCELE

*S. Andò*

I. Introduction	201
II. Hormone Peripheral Levels	203
III. Hormone Spermatogenic Venous Blood Levels	217
IV. Hormone Seminal Plasma Levels	223
V. Closing Remarks	227
References	228

## 13 / VARICOCELE: FACT OR FICTION?

*Nelson Rodrigues-Netto, Jr.*

I. Introduction	233
II. Influence of Varicocele on Fertility	235
III. Influence of a Varicocele on Spermatogenesis: Pathophysiology	235
IV. Experimental Models for Research Purposes	240
V. Diagnosis	241
VI. Semen Analysis: Morphology	244
VII. Treatment	244
References	248

## 14 / VARICOCELE AND MALE INFERTILITY

*Frank H. Comhaire*

I. Epidemiology	253
II. Physiopathology of Testicular Dysfunction in Varicocele Infertility	253
III. Diagnosis of Varicocele	255
IV. Effect of Varicocele on Testicular Function	259
V. Endocrine Investigations	260
VI. Treatment of Varicocele	260
VII. Treatment Results of Transcatheter Embolization with Tissue Adhesive	263
VIII. Conclusions	266
References	267

#### IV / Male Reproductive Tract and Testicular Function

### 15 / EPIDIDYMAL MARKERS AND SPERM ANALYSIS

*Roland R. Tremblay*

I. Introduction	273
II. Evidence for Epididymal Origin of $\alpha$ -1,4-Glucosidase	274
III. Hormonal Control of $\alpha$ -1,4-Glucosidases	281
IV. Clinical Data	283
V. Concluding Remarks	289
References	290

### 16 / SPERMATOGONIAL PROLIFERATION: ROLE OF THE CHALONES

*Eduardo Bustos-Obregón*

I. Introduction	293
II. Material and Methods	295
III. Results	299
IV. Discussion	304
References	310

### 17 / IMMUNOELECTRON MICROSCOPY OF HUMAN SPERM

*Lucia Castellani-Ceresa and Roberto Colombo*

I. Introduction	313
II. Immunochemical Bases	313
III. Immunoelectron Microscopic Studies on Mammalian Spermatozoa	319
IV. Immunoelectron Microscopic Studies on Human Spermatozoa	321
V. Conclusions	326
References	326

### 18 / INTERACTION BETWEEN SEMINAL PLASMA AND SPERMATOZOA

*R. Eliasson and Ø. Johnsen*

I. Introduction	331
II. Origin and Emission of the Seminal Plasma	332
III. Interaction with Metal Ions	332
IV. Motility and Metabolism of the Spermatozoa	334
V. Lipid Peroxidation	335
VI. Chromatin Stability and Condensation	336
VII. Fertilizing Ability	336
VIII. Xenobiotic Factors	337

IX. Conclusions	337
References	339

## 19 / SPERM ANALYSIS IN THE INFERTILE MALE

*G. F. Menchini-Fabris, S. Voliani, D. Canale,  
and L. Olivieri*

I. Introduction	341
II. Sample Collection	342
III. Preliminary Observations	343
IV. Sperm Count	344
V. Motility Evaluation	346
VI. Morphological Analysis	346
VII. Spermatogenic Cells and Meiosis Analysis	349
VIII. Viability	351
IX. Agglutinates	351
X. Biochemical Examination of Semen	352
XI. Epididymal Fluid	352
XII. Seminal Vesicle Secretion	353
XIII. Prostatic Fluid	354
References	355

## 20 / THE PROACROSIN-ACROSIN SYSTEM

*Kenneth L. Polakoski and Mark S. Siegel*

I. Introduction	359
II. Proacrosin	360
III. Multiple Forms of Acrosin	362
IV. Characterization of Acrosin	363
V. Acrosin Inhibitors	364
VI. Function of Acrosin	365
VII. Location of Acrosin	367
VIII. Clinical Implications	368
References	369

## 21 / THE USE OF LABORATORY TECHNIQUES IN IMPROVEMENT OF SPERM QUALITY

*Gedalia F. Paz, Avraham Kogosowski, Leah Yogev,  
and Zwi T. Homonnai*

I. Introduction	377
II. Semen Analysis	378
III. Improvement of Sperm Quality in Nonliquefied Specimens	379
IV. Improvement of Sperm Quality by Centrifugation Technique	381
V. Improvement of Sperm Quality by the Use of Albumin Columns	383

VI. Improvement of Sperm Quality by Filtration of Semen through Bovine Cervical Mucus	384
VII. The Use of Drugs for <i>in Vitro</i> Improvement of Sperm Quality	385
VIII. Artificial Insemination with Husband's Semen (AIH)	388
IX. Summary and Conclusions	390
References	391

## V / Immunoandrology and Local Factors

### 22 / ANTIBODY FACTORS IN INFERTILITY WITH REFERENCE TO DIAGNOSIS, SIGNIFICANCE, AND TREATMENT

*Sidney Shulman*

I. Basic Axioms of Immunologic Infertility	399
II. Historical Perspective	400
III. The Wide Range of Serological Methods	401
IV. Significance of Antibody Findings	404
V. The Prevalence of Sperm Antibody Occurrence	404
VI. Local Immunity in Antibody Activity	406
VII. Treatment of Immunologic Infertility: Efforts at Immunosuppression	406
References	411

### 23 / IMMUNOINFERTILITY

*Salvatore Leto and John D. Paulson*

I. Introduction	415
II. Clinical Observations of Immunoinfertility and Circulating Antibodies	415
III. Immunology and the Reproductive Tract	416
IV. Sperm Agglutination Techniques	417
V. Sperm Cytotoxicity Methods	418
VI. Clinical Significance of Antisperm Antibodies	420
VII. Treatment	421
VIII. Clinical Observations	423
IX. Summary	424
References	424

### 24 / SPERM-CERVICAL MUCUS INTERWORKINGS

*Robert F. Harrison*

I. Introduction	427
II. Biophysics	427
III. Biochemistry	427
IV. Functional Anatomy	429
V. Function	430
VI. Investigation	431



VII. Immunological	440
VIII. Conclusions	443
References	443

## 25 / CERVICAL MUCUS IN IMMUNOINFERTILITY

*Salvatore Leto and John D. Paulson*

I. Introduction	451
II. Reported Clinical Findings	452
III. Cervical Mucus Test Methods	453
IV. Clinical Observations	453
V. Summary	455
References	456

## VI / Artificial Insemination

## 26 / ARTIFICIAL INSEMINATION

*B. Norman Barwin*

I. Introduction	461
II. History	461
III. Incidence	462
IV. Psychological Aspects	462
V. Ethical and Legal Aspects	463
VI. Preparation	463
VII. Female Partner	463
VIII. Indications for AIH	464
IX. Indications for AID	465
X. Selection of Donor	465
XI. Technique	466
XII. Timing of Insemination	467
XIII. Results of AIH	467
XIV. Results of AID with Fresh Semen	468
XV. Results of AID with Frozen Sperm	470
XVI. Semen Preservation	471
XVII. Technical Aspects—The Advantages of Frozen Semen	471
XVIII. Duration of Insemination	472
XIX. Conclusion	472
References	472

## 27 / SPERM MANIPULATION FOR USE IN ARTIFICIAL INSEMINATION

*John D. Paulson and Evelyn Karson*

I. Introduction	475
II. Albumin Columns	475
III. Glass Wool Column Filtration	477
IV. Use of Pharmacologic Agents	479
V. Kallikrein/Kinin System	481
VI. Prostaglandins	482